This information was published on 2025-01-13T00:16:05 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2510945 (IR 1831173) |
| (220) |
22 Nov 2024
|
| (300) |
US, 12 Aug 2024, 98694164
|
| (511) (510) |
Class 5
Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, neurological diseases and disorders, and ophthalmic diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome, macular degeneration, geographic atrophy, Huntington's disease, amyotrophic lateral sclerosis (ALS), lupus, cold agglutinin disease (CAD), chronic inflammatory demyelinating polyneuropathy (CIDP), and myasthenia gravis (MG). Class 42 Pharmaceutical research and development; consulting services in the field of pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Class 44 Providing medical information; providing medical information related to pharmaceuticals. |
| (540) | ANNEXON |
| (550) | Word |
| (730) |
Annexon, Inc.
|
Find out more about publications on the About page.